Source: Profil Institute for Clinical Research, Inc. & reported by http://www.prnewswire.com/
SAN DIEGO and SHENZHEN, China, July 28, 2016 /PRNewswire/ -- Profil Institute for Clinical Research, Inc., a science-driven clinical research organization (CRO) focused exclusively on metabolic diseases, announced today a strategic master services agreement with Shenzhen HighTide Biopharmaceutical Ltd., a subsidiary of Shenzhen Hepalink Pharmaceutical Co., Ltd.
Under the terms of the agreement, Profil Institute will provide clinical research and development services, from IND readiness through the completion of early phase development, including regulatory and scientific support services, for HighTide's portfolio of drug candidates that address the therapeutic areas of diabetes and NAFLD/NASH.
HighTide is a US-China joint venture founded in 2011 by Dr. Liping Liu and Hepalink Pharmaceutical to progress a promising portfolio of novel therapeutic candidates from discovery to clinical development for the treatment of diabetes and NAFLD/NASH.
Profil Institute is a leading early phase CRO focused exclusively on metabolic diseases. Its experience encompasses a wide range of investigational and marketed drugs for diabetes, obesity and NAFLD/NASH, with more than 280 clinical research projects completed.
Read more: http://www.prnewswire.com/news-releases/profil-institute-and-hightide-biopharmaceutical-announce-a-strategic-partnership-focused-on-the-development-of-new-therapies-for-diabetes-and-nafldnash-300305293.html